Summary

India monoclonal antibodies market is expected to grow at a steady rate during the forecast period. In biochemistry and molecular biology, monoclonal antibodies play an important role as they can detect and purify substances. These are derived from the identical immune cells and can easily bind to a particular antigen. The invention of new applications in monoclonal antibodies in addition to growing investment in R&D for improving healthcare infrastructure is significantly influencing the growth rate of the monoclonal antibodies in the country. The advancement of genomics research as well as emergence of the technologically advanced genetic platforms has contributed to the growth of monoclonal antibodies market. The emergence of advanced technology and launch of innovative products in the biotechnology field has led to the growth of monoclonal antibodies. However, less availability of the raw materials used for the manufacturing of drugs is the major challenge in the growth of monoclonal antibodies market.

The India monoclonal antibodies market is segmented based on type, application, production, biomanufacturing, end users, company and region. Based on type, murine segment is expected to dominate the market share in the forecast period. Increase in the number of people suffering from various health disorders is expected to drive the growth of the segment through FY2026. Based on end user, hospitals segment is expected to dominate the market share in the forecast period. Due to increase in geriatric population and improvement in healthcare infrastructure, this segment is expected to dominate the market share in the forecast period.

Major players operating in the India monoclonal antibodies market include Novartis India Limited, Dr. Reddy’s Laboratories Ltd., Bristol Myers Squibb India Pvt. Ltd., Roche India Pvt. Ltd., Intas Pharmaceuticals Limited, Merck India, Eli Lilly, and Company (India) Private Limited, Biocon Limited, AstraZeneca India Pvt. Ltd., Pfizer Limited and others. The companies are developing advanced technologies and launching new products to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.
Years considered for this report:
Historical Years: FY2016-FY2019
Base Year: FY2020
Estimated Year: FY2021
Forecast Period: FY2022–FY2026
Objective of the Study:
• To analyze and estimate the market size of India monoclonal antibodies market from FY2016 to FY2020.
• To estimate and forecast the market size of India monoclonal antibodies market from FY2021 to FY2026 and growth rate until FY2026.
• To classify and forecast India monoclonal antibodies market based on type, application, production, biomanufacturing, end users, company and regional distribution.
• To identify dominant region or segment in the India monoclonal antibodies market.
• To identify drivers and challenges for India monoclonal antibodies market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in India monoclonal antibodies market.
• To identify and analyze the profile of leading players operating in India monoclonal antibodies market.
• To identify key sustainable strategies adopted by market players in India monoclonal antibodies market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the country.
TechSci Research calculated the market size of India monoclonal antibodies market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
• Monoclonal antibodies manufacturers, suppliers, distributors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to monoclonal antibodies
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, India monoclonal antibodies market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• India Monoclonal Antibodies Market, By Type:
o Murine
o Chimeric
o Humanized
o Human
• India Monoclonal Antibodies Market, By Application:
o Cancer
o Cardiac/Cardiovascular
o Neurological
o Others
• India Monoclonal Antibodies Market, By Production:
o In vitro
o In vivo
• India Monoclonal Antibodies Market, By Biomanufacturing:
o Originator
o CMO
• India Monoclonal Antibodies Market, By End users:
o Hospitals
o Research Laboratories
o Others
• India Monoclonal Antibodies Market, By Region:
o North
o South
o East
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in India monoclonal antibodies market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents